GlycoMinds

Executive Summary

GlycoMinds is a San Diego-based diagnostics company focused on the differential diagnosis of inflammatory bowel disease (IBD) through its proprietary IBDX® serological panel. The IBDX panel is the most validated and cost-effective tool for distinguishing IBD from non-IBD conditions and differentiating Crohn's disease (CD) from ulcerative colitis (UC), while also predicting the probability of Crohn's disease progression. Despite being founded in 2001 and operating as a private company, GlycoMinds has established its product as a standard-of-care in gastroenterology, offering significant clinical and economic value by reducing the need for invasive procedures and enabling earlier, more accurate treatment decisions.

Upcoming Catalysts (preview)

• Q3 2026Publication of large-scale real-world validation study for IBDX80% success
• Q1 2027Inclusion of IBDX in updated clinical practice guidelines from major GI societies60% success
• Q2 2027Launch of next-generation IBDX plus panel with expanded biomarker coverage70% success